Prelude Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $546K | Sell |
60,897
-39,003
| -39% | -$349K | 0.05% | 411 |
|
|
2025
Q1 | $749K | Buy |
+99,900
| New | +$749K | 0.06% | 326 |
|
|
2024
Q4 | – | Sell |
-38,900
| Closed | -$296K | – | 1099 |
|
|
2024
Q3 | $296K | Buy |
+38,900
| New | +$296K | 0.02% | 786 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 1385 |
|
|
2020
Q2 | – | Sell |
-24,433
| Closed | -$49K | – | 1328 |
|
|
2020
Q1 | $49K | Buy |
+24,433
| New | +$49K | ﹤0.01% | 478 |
|
|
2019
Q3 | – | Sell |
-3,587
| Closed | -$14K | – | 1196 |
|
|
2019
Q2 | $14K | Buy |
+3,587
| New | +$14K | ﹤0.01% | 964 |
|
|
2018
Q4 | – | Sell |
-1,318
| Closed | -$10K | – | 1400 |
|
|
2018
Q3 | $10K | Buy |
+1,318
| New | +$10K | ﹤0.01% | 1095 |
|
|
2017
Q2 | – | Sell |
-800
| Closed | -$7K | – | 1485 |
|
|
2017
Q1 | $7K | Buy |
+800
| New | +$7K | ﹤0.01% | 1319 |
|
|
2016
Q3 | – | Sell |
-24,700
| Closed | -$70K | – | 1514 |
|
|
2016
Q2 | $70K | Buy |
24,700
+18,700
| +312% | +$53K | 0.01% | 838 |
|
|
2016
Q1 | $17K | Buy |
+6,000
| New | +$17K | ﹤0.01% | 1054 |
|
|
2015
Q2 | – | Sell |
-800
| Closed | -$7K | – | 1599 |
|
|
2015
Q1 | $7K | Sell |
800
-3,700
| -82% | -$32.4K | ﹤0.01% | 1765 |
|
|
2014
Q4 | $55K | Buy |
4,500
+1,200
| +36% | +$14.7K | 0.01% | 1120 |
|
|
2014
Q3 | $32K | Buy |
3,300
+700
| +27% | +$6.79K | ﹤0.01% | 1511 |
|
|
2014
Q2 | $33K | Buy |
+2,600
| New | +$33K | ﹤0.01% | 1451 |
|